LULL(ed) into complacency: a perspective on licenses and stem cell translational science
50 South Drive, Suite 1140, Bethesda, MD 20892, USA
Stem Cell Research & Therapy 2013, 4:98 doi:10.1186/scrt309Published: 14 August 2013
The US has had a very successful model for facilitating the translation of a basic discovery to a commercial application. The success of the model has hinged on providing clarity on ownership of a discovery, facilitating the licensing process, providing adequate incentive to the inventors, and developing a self-sustaining model for reinvestment. In recent years, technological, political, and regulatory changes have put strains on this model and in some cases have hindered progress rather than facilitated it. This is particularly true for the nascent field of regenerative medicine. To illustrate this, I will describe the contributing practices of several different entities, including universities, repositories, patent trolls, and service providers. It is my hope that the scientific community will be motivated to coordinate efforts against these obstacles to translation.